{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:29:53Z","timestamp":1792002593780,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016627","name":"Anticancer Fund","doi-asserted-by":"publisher","award":["40117"],"award-info":[{"award-number":["40117"]}],"id":[{"id":"10.13039\/100016627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016627","name":"Anticancer Fund","doi-asserted-by":"publisher","award":["N19PCA A59"],"award-info":[{"award-number":["N19PCA A59"]}],"id":[{"id":"10.13039\/100016627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.113974","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T22:47:21Z","timestamp":1709333241000},"page":"113974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Propranolol monotherapy in angiosarcoma \u2013 A window-of-opportunity study (PropAngio)"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-771X","authenticated-orcid":false,"given":"Alaa","family":"Embaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley M.","family":"Heinhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki S.","family":"IJzerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Miek","family":"Koenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"van der Kleij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"van Boven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0551-7813","authenticated-orcid":false,"given":"Joyce","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winette T.A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-4331","authenticated-orcid":false,"given":"Rick L.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-3468","authenticated-orcid":false,"given":"Winan J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2279","authenticated-orcid":false,"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.113974_bib1","series-title":"Soft Tissue and Bone Tumours WHO Classification of Tumours","year":"2020"},{"issue":"5","key":"10.1016\/j.ejca.2024.113974_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/COC.0b013e31827e4e7b","article-title":"Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience","volume":"37","author":"Buehler","year":"2014","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2024.113974_bib3","first-page":"983","volume":"11","author":"Young","year":"2010","journal-title":"Angiosarcoma"},{"issue":"1","key":"10.1016\/j.ejca.2024.113974_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1245\/s10434-022-12601-1","article-title":"Prognosis of patients with cutaneous angiosarcoma after surgical resection with curative intent: is there a difference between the subtypes?","volume":"30","author":"Reijers","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113974_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/1078-0432.CCR-19-2180","article-title":"DNA methylation profiling identifies distinct clusters in angiosarcomas","volume":"26","author":"Weidema","year":"2020","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2024.113974_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082251","article-title":"Neoadjuvant systemic treatment of primary angiosarcoma","volume":"12","author":"Heinhuis","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ejca.2024.113974_bib7","first-page":"2303","article-title":"Angiosarcoma: a review of diagnosis and current treatment","volume":"9","author":"Cao","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ejca.2024.113974_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2022.04.030","article-title":"Chemotherapy in patients with localized angiosarcoma of any site: a retrospective european study","volume":"171","author":"Conforti","year":"2022","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"10.1016\/j.ejca.2024.113974_bib9","doi-asserted-by":"crossref","unstructured":"Stiles J.M., Amaya C., Rains S., Diaz D., Pham R., Battiste J., et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. 2013;8(3):e60021.","DOI":"10.1371\/journal.pone.0060021"},{"issue":"11","key":"10.1016\/j.ejca.2024.113974_bib10","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2012.108","article-title":"\u03b2-Adrenergic receptor expression in vascular tumors","volume":"25","author":"Chisholm","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2024.113974_bib11","volume":"9","author":"Qiao","year":"2018","journal-title":"Adren Signal: A Targeta Checkp Limit Dev Antitumor Immune Response"},{"key":"10.1016\/j.ejca.2024.113974_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/JEP.S146211","article-title":"Propranolol for the treatment of vascular sarcomas","volume":"10","author":"Wagner","year":"2018","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.ejca.2024.113974_bib13","unstructured":"Hemangeol FDA approval [Available from: \u3008https:\/\/www.drugs.com\/history\/hemangeol.html\u3009."},{"key":"10.1016\/j.ejca.2024.113974_bib14","unstructured":"Hemangiol EMA approval [Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemangiol\u3009."},{"key":"10.1016\/j.ejca.2024.113974_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940582","article-title":"Beta-adrenergic receptor blockade in angiosarcoma: which beta-blocker to choose?","volume":"12","author":"Embaby","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.113974_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156863","article-title":"A transcription factor is the target of propranolol treatment in infantile hemangioma","volume":"132","author":"Schrenk","year":"2022","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.ejca.2024.113974_bib17","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","article-title":"Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment","volume":"41","author":"Fj\u00e6stad","year":"2022","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ejca.2024.113974_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"issue":"9","key":"10.1016\/j.ejca.2024.113974_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039449","article-title":"PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study","volume":"10","author":"Heinhuis","year":"2020","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.ejca.2024.113974_bib20","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/jamadermatol.2015.2554","article-title":"Growth attenuation of cutaneous angiosarcoma with propranolol-mediated \u03b2-blockade","volume":"151","author":"Chow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2024.113974_bib21","unstructured":"Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) [cited 2023 28\u201311-2023]. Available from: \u3008https:\/\/radiopaedia.org\/articles\/positron-emission-tomography-response-criteria-in-solid-tumors-percist-1\u3009."},{"key":"10.1016\/j.ejca.2024.113974_bib22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017 [Available from: \u3008https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5\u00d77.pdf\u3009."},{"issue":"9-10","key":"10.1016\/j.ejca.2024.113974_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.18632\/oncoscience.472","article-title":"Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment","volume":"5","author":"Galv\u00e1n","year":"2018","journal-title":"Oncoscience"},{"key":"10.1016\/j.ejca.2024.113974_bib24","unstructured":"Summary of Product Characteristics - Propranolol 40 mg film-coated tablets - Electronic Medicines Compendium (EMC) [Available from: \u3008https:\/\/www.medicines.org.uk\/emc\/product\/12859\u3009."},{"issue":"2","key":"10.1016\/j.ejca.2024.113974_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.113974_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13073-020-00753-2","article-title":"Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing","volume":"12","author":"Boichard","year":"2020","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.ejca.2024.113974_bib27","doi-asserted-by":"crossref","first-page":"Fso691","DOI":"10.2144\/fsoa-2020-0211","article-title":"Prognostic implications of PD-L1 expression in patients with angiosarcoma","volume":"7","author":"Lee","year":"2021","journal-title":"Future Sci OA"},{"issue":"2","key":"10.1016\/j.ejca.2024.113974_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12026-021-09259-4","article-title":"Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups","volume":"70","author":"Tomassen","year":"2022","journal-title":"Immunol Res"},{"key":"10.1016\/j.ejca.2024.113974_bib29","unstructured":"Clinicaltrials.gov - PROPANE study [Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05961761?cond=angiosarcoma&intr=propranolol&rank=3#participation-criteria\u3009."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:34:59Z","timestamp":1778517299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":29,"alternative-id":["S0959804924001308"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113974","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Propranolol monotherapy in angiosarcoma \u2013 A window-of-opportunity study (PropAngio)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113974"}}